LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

Kodu・Aktsiate loetelu・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Avatud

SektorTervishoid

34.61 4.28

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

32.83

Max

34.97

Põhinäitajad
By Trading Economics
Sissetulek	11M 51M
Müük	39M 239M
P/E Sektori keskmine	10.722 106.172
Aktsiakasum	1.08
Kasumimarginaal	21.242
Töötajad	268
EBITDA	14M 73M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+38.1% upside

Turustatistika
By TradingEconomics
Turukapital	270M 2B
Eelmine avamishind	30.33
Eelmine sulgemishind	34.61

Uudiste sentiment

By Acuity

55%

45%

324 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

29.8 / N/A Toetus ja vastupanu

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. nov 2025, 23:07 UTC

Market Talk

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

20. nov 2025, 22:22 UTC

Market Talk

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

20. nov 2025, 22:08 UTC

Market Talk

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

20. nov 2025, 21:57 UTC

Tulu

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

20. nov 2025, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

20. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20. nov 2025, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

20. nov 2025, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

20. nov 2025, 21:31 UTC

Tulu

Nvidia's Strong Results Show AI Fears Are Premature -- Update

20. nov 2025, 21:23 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20. nov 2025, 21:07 UTC

Tulu

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20. nov 2025, 21:06 UTC

Tulu

Webull 3Q Rev $156.9M >BULL

20. nov 2025, 21:06 UTC

Tulu

Webull 3Q EPS 7c >BULL

20. nov 2025, 21:05 UTC

Tulu

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

20. nov 2025, 21:04 UTC

Tulu

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

20. nov 2025, 21:04 UTC

Tulu

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

20. nov 2025, 21:04 UTC

Tulu

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

20. nov 2025, 21:00 UTC

Tulu

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

20. nov 2025, 21:00 UTC

Tulu

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 Rev $21B-$21.19B >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit 1Q Consumer Rev $894M

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 Guidance

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit 1Q Global Business Solutions Rev $3B

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

38.1% tõus

12 kuu keskmine prognoos

Keskmine 46 USD 38.1%

Kõrge 62 USD

Madal 32 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Harmony Biosciences Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

29.8 / N/AToetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

324 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.